Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2018 Jul 4:13:35.
doi: 10.1186/s13020-018-0192-y. eCollection 2018.

Anticancer drug discovery from Chinese medicinal herbs

Affiliations
Review

Anticancer drug discovery from Chinese medicinal herbs

Mu-Yang Huang et al. Chin Med. .

Abstract

Cancer is still presenting a serious threat to human health worldwide. The understanding of the complex biology of cancer and the development of oncotherapy have led to increasing treatment approaches such as targeted therapy and immunotherapy. Chinese medicinal herbs have attracted considerable attention due to their potential anticancer effects. Some natural products or formulae from Chinese medicinal herbs with directly or indirectly anticancer effects have been reported. In this article, we summarized the current progression on development of anticancer drugs from Chinese medicinal herbs, toward providing ideas for further development and application of Chinese medicinal herbs in cancer therapy.

Keywords: Anticancer; Chinese medicinal herbs; Drug discovery; Formulae; Natural products.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
Chemical structures of the natural products. a magnolol; b oleanolic acid; c curcumin; d toosendanin; e camptothecin; f tanshinone I; g artemisinin; h nitidine chloride; i ginsenoside Rg1; j baicalein; k astragaloside IV; l platycodin D; m celastrol; n ginsenoside Rg3; o berberine
Fig. 2
Fig. 2
Potential anticancer mechanisms of Chinese medicinal herbs
Fig. 3
Fig. 3
Anticancer drug development strategies from Chinese medicinal herbs

References

    1. Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics, 2012. CA Cancer J Clin. 2015;65:87–108. doi: 10.3322/caac.21262. - DOI - PubMed
    1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2016. CA Cancer J Clin. 2016;66:7–30. doi: 10.3322/caac.21332. - DOI - PubMed
    1. Chen W, Zheng R, Baade PD, Zhang S, Zeng H, Bray F, et al. Cancer statistics in China, 2015. CA Cancer J Clin. 2016;66:115–132. doi: 10.3322/caac.21338. - DOI - PubMed
    1. Arruebo M, Vilaboa N, Saez-Gutierrez B, Lambea J, Tres A, Valladares M, et al. Assessment of the evolution of cancer treatment therapies. Cancers. 2011;3:3279–3330. doi: 10.3390/cancers3033279. - DOI - PMC - PubMed
    1. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144:646–674. doi: 10.1016/j.cell.2011.02.013. - DOI - PubMed

LinkOut - more resources